a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to ...

Results of another phase 2b study – called SYMMETRY – showed that efruxifermin was unable to hit its main objective as a treatment for patients with compensated cirrhosis (F4) due to NASH ...

Shares of Akero Therapeutics more than doubled in response to startlingly positive data on its liver drug efruxifermin, which the biotech said reversed liver scarring in patients with advanced ...

A 50-milligram dose of efruxifermin resulted in the reversal of cirrhosis in 39% of the patients while none of them experienced any further worsening of MASH, as per the company’s press release.

The company’s primary product is efruxifermin (EFX), which treats MASH and is undergoing phase 3 of clinical trials. Efruxifermin (EFX) is an analog of fibroblast growth factor 21, an ...

Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcohol-related liver disease. MASH is linked to a ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with ...

UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...

The company’s primary product is efruxifermin (EFX), which treats MASH and is undergoing phase 3 of clinical trials. Efruxifermin (EFX) is an analog of fibroblast growth factor 21, an ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...